“Cullinan is strategically focusing resources and development efforts on select, high-conviction clinical stage programs. We are well-positioned to further concentrate resources on CLN-978, a CD19xCD3 bispecific T cell engager, and we plan to share initial clinical data in autoimmune diseases in the first half of 2026. We are also particularly encouraged by the emerging efficacy profile of CLN-049, our FLT3xCD3 bispecific T cell engager, and we look forward to unveiling important clinical data in an oral presentation at the upcoming 2025 ASH Annual Meeting in December. We believe the differentiated mechanism of CLN-049 supports its potential to address a broad population of AML patients regardless of mutational status, including those with poor prognostic features,” said Nadim Ahmed, Chief Executive Officer of Cullinan Therapeutics (CGEM).
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CGEM:
- Promising Phase 1 Results for CLN-049 in AML Justify Buy Rating
- Cullinan Management Unveils Promising CLN-049 Clinical Data
- Cullinan Therapeutics to showcase new data from Phase 1 study of CLN-049
- Promising Clinical Trial Results and Strategic Partnerships Drive Buy Rating for Cullinan Management
- Buy Rating for Cullinan Management’s Zipalertinib: Promising Efficacy in Challenging EGFR Mutated NSCLC Cases